Nevro Announces American Association of Clinical Endocrinology Clinical Practice Guideline Has Been Updated to Include High-Frequency 10 kHz Spinal Cord Stimulation to Treat Painful Diabetic Neuropathy

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that Nevro’s HFX 10 kHz Therapy is the only form of spinal cord stimulation (SCS) therapy to be referenced by the American Association of Clinical Endocrinology (AACE) in its 2022 Diabetes Clinical Practice Guideline to treat painful diabetic neuropathy (PDN).

Based on results from Nevro’s landmark SENZA-PDN randomized controlled study, the AACE guideline states that high frequency (e.g., 10 kHz) spinal cord stimulation is a nonpharmacological approach that may be effective in persons with painful diabetic peripheral neuropathy that failed at least one medication.¹,²  The treatment algorithm in the guideline also includes a referral to a pain physician for assessment if medical therapy has failed.

“For a clinician specializing in providing care for patients with diabetes, helping those with intractable pain of peripheral diabetic neuropathy is probably the most frustrating aspect of my practice,” commented Dr. George Grunberger, Chairman of the Grunberger Diabetes Institute in Bloomfield Hills, Michigan and Past President of the American Association of Clinical Endocrinologists.  “There is a dearth of effective medications approved by the FDA for its management, and none of these are disease modifying.  Medications which are being used are in many cases ineffective and/or associated with side effects.  Of course, their use also necessitates life-long adherence.  It was thus welcome news when the FDA approved high-frequency spinal cord stimulation for the management of PDN and also encouraging to see that its use for these patients is listed in the latest update of the AACE guideline for comprehensive care planning for diabetes.”

“This is a very positive endorsement of our proprietary, high-frequency 10 kHz Therapy by an important community of health care providers specializing in endocrinology, diabetes, and metabolic disorders,” stated D. Keith Grossman, Chairman, CEO and President of Nevro.  “Based on our strong and growing body of published, peer-reviewed clinical trial data that demonstrated twice the patient responder rate, twice the pain relief and the only study to demonstrate neurologic improvements, we believe that our HFX solution is uniquely positioned to provide relief to the thousands of patients suffering from PDN.”

The 2022 guideline update synthesizes thousands of articles to provide health care professionals with the latest evidence-based information on the total care of diabetes.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The ArthroFree system is the first FDA-cleared wireless camera for arthroscopy and general endoscopy, both areas of minimally invasive surgery. The system is designed to help surgeons work with aximum dexterity and focus.
The project, which was led by the University of Southern California, included large increases in representation among men of African, Hispanic and Asian ancestries, that were contributed in part by an ongoing collaboration between the U.S. Department of Veterans Affairs and DOE reports Argonne.
This innovative software turns smartphones into medical-grade stethoscopes, allowing people to capture, analyze, and share critical heart health data with medical personnel from the comfort of any location notes Sparrow BioAcoustics.
"Taewoong Medical becoming an Olympus group company is also a major milestone in our global growth strategy," said Henry Shin, CEO of STARmed. "We look forward to our products being made available to more patients through Olympus' global distribution network."
The company reports they have successfully met the six-month primary endpoint for the first-ever female patient implanted with the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) to treat SUI.

By using this website you agree to accept Medical Device News Magazine Privacy Policy